Selling, General, and Administrative Costs: AbbVie Inc. vs Madrigal Pharmaceuticals, Inc.

A Tale of Two Companies: SG&A Expenses Over Time

In the world of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. Over the past decade, AbbVie Inc. and Madrigal Pharmaceuticals, Inc. have shown contrasting trends in their SG&A costs. AbbVie, a giant in the industry, saw its SG&A expenses grow by approximately 66% from 2014 to 2023, peaking in 2022. This increase reflects its expansive operations and strategic investments. In contrast, Madrigal Pharmaceuticals, a smaller player, experienced a staggering 587% rise in SG&A expenses over the same period, indicating aggressive growth and expansion efforts. While AbbVie's expenses are significantly higher in absolute terms, the rapid increase in Madrigal's costs highlights its ambitious trajectory in the competitive pharmaceutical landscape. Understanding these trends offers valuable insights into each company's strategic priorities and market positioning.